The American College of Radiology and other prominent health groups recently launched a national registry to gather real-world data on the newest treatments for Alzheimer’s disease.
The National Treatment and Diagnostic Alzheimer’s Registry will include experimental approaches and FDA-approved treatments, such as Aduhelm, along with associated diagnostic tests and biomarkers. Other collaborators include the Alzheimer’s Association, the American Society of Neuroradiology and Brown University’s Department of Biostatistics.
The overarching goal is to capture patient-level information on the newest FDA-approved, disease-modifying treatments.
"There is an urgent unmet need to provide effective treatments for all who need them, and a transparent approach that allows for immediate sharing of data will not only accelerate advances, but identify gaps in effectiveness and safety, and highlight opportunities to improve care and treatment for all affected by Alzheimer's," Alzheimer’s Association Chief Science Officer Maria C. Carrillo, PhD, said in a statement.
The Alzheimer’s Association is putting up the initial investment for the project and will then ask for additional funding from government and other organizations.
Additionally, Carrillo said the living document will help government and regulatory agencies with decisions related to policy, education, approvals and grants.
Read more here.
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.